ETH Zurich’s Versantis picked up series B funding from Zürcher Kantonalbank among other returning investors to bring its total to $20.6m.

Versantis, a Switzerland-based biotherapeutics spinout of ETH Zurich focused on rare liver and pediatric diseases, has closed a CHF16m ($16.2m) round led by Swisscanto Invest, an asset management arm of financial services firm Zürcher Kantonalbank.
Zürcher Kantonalbank subsidiary Start-up Finance also participated, as did health savings account provider HealthEquity, venture firm Redalpine Venture Partners, investment platform Investiere and Esperante Ventures, a venture firm run by life sciences holdings group C&P, also took part. Assorted angel investors filled out the…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?